Caleco To Initiate Clinical Studies For Lamiridosin

Caleco Pharma (Caleco) has initiated the clinical studies of Lamiridosin in collaboration with Puleva Biotech (Puleva) to evaluate the effectiveness of Lamiridosin, a dietary supplement that the company is in the process of developing. Reportedly, Lamiridosin is designed to treat patients with the Hepatitis C virus and is derived from the company’s proprietary technology that it refers to as the Liver Health Formula.

David Peralta, CFO and COO of NanoBio, said: “NanoBio’s nanoemulsion-based vaccine adjuvant platform has consistently demonstrated the ability to elicit robust systemic, cellular and mucosal immunity, based on studies we’ve conducted in numerous diseases using various antigen types. This award will fund extensive additional research that will allow NanoBio and the University of Michigan to further advance our adjuvant platform for vaccines.”

The company has said that the aim of the clinical study will be to demonstrate whether there is a benefit using the supplement in treating patients who have the Hepatitis C virus in conjunction with the current conventional treatment of the Hepatitis C virus.

Moreover, the company plans to conduct the clinical study by recruiting patients with the Hepatitis C virus. It also plans to collaborate with different Spanish researchers who are focusing on Hepatitis C treatment.

“Our unique approach to inducing immunity leverages nasal immune elements to produce a level of protective immunity not seen with currently available vaccines. This funding will enable NanoBio to make tremendous advances in terms of mucosal vaccination, which could provide significant advantages with respect to disease protection worldwide,” Mr. Peralta added.